A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 20 Jun 2019 Planned End Date changed from 21 Feb 2022 to 25 Feb 2022.
- 20 Jun 2019 Planned primary completion date changed from 14 Feb 2020 to 25 Feb 2022.
- 20 Jun 2019 Status changed from recruiting to active, no longer recruiting.